Quantitative Proteomics Identification of Phosphoglycerate Mutase 1 As a Novel Therapeutic Target in Hepatocellular Carcinoma

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2010 Apr 21

PMID 20403181

Citations 65

Authors

Fenglian Ren

Hong Wu

Yunlong Lei

Haiyuan Zhang

Rui Liu

Yong Zhao

Xiancheng Chen

Dequan Zeng

Aiping Tong

Lijuan Chen

Yuquan Wei

Canhua Huang

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with poor prognosis due to resistance to conventional chemotherapy and limited efficacy of radiotherapy. There is an urgent need to develop novel biomarkers for early diagnosis, as well as to identify new drug targets for therapeutic interventions.

Patients And Methods: 54 paired HCC samples and 21 normal liver tissues were obtained from West China Hospital of Sichuan University. Informed consent was obtained from all the patients or their relatives prior to analysis, and the project was approved by the Institutional Ethics Committee of Sichuan University. Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC)-based proteomics was employed to profile the differentially expressed proteins between a HepG2 human hepatoma cell line and an immortal hepatic cell line L02. Validation of PGAM1 expression was performed by semi-quantitative RT-PCR, immunoblot and immunohistochemistry using clinical samples. shRNA expressing plasmids specifically targeting PGAM1 were designed and constructed by GenePharma Corporation (Shanghai, China), and were utilized to silence expression of PGAM1 in vitro and in vivo. Cell proliferation was measured by a combination of colony formation assay and Ki67 staining. Apoptosis was examined by flow cytometry and TUNEL assay.

Results: A total of 63 dysregulated proteins were identified, including 51 up-regulated proteins, and 12 down-regulated proteins (over 2-fold, p < 0.01). Phosphoglycerate mutase 1 (PGAM1) was found markedly upregulated. Clinico-pathological analysis indicated that overexpression of PGAM1 was associated with 66.7% HCC, and strongly correlated with poor differentiation and decreased survival rates (p < 0.01). shRNAs-mediated repression of PGAM1 expression resulted in significant inhibition in liver cancer cell growth both in vitro and in vivo.

Conclusion: Our studies suggested that PGAM1 plays an important role in hepatocarcinogenesis, and should be a potential diagnostic biomarker, as well as an attractive therapeutic target for hepatocellular carcinoma.

Citing Articles

PGAM1: a potential therapeutic target mediating Wnt/β-catenin signaling drives breast cancer progression.

Wang Y, Liu W, Lai X, Miao H, Xiong X Discov Oncol. 2025; 16(1):161.

PMID: 39934550 PMC: 11814419. DOI: 10.1007/s12672-025-01939-z.

Thermal proteome profiling reveals fructose-1,6-bisphosphate as a phosphate donor to activate phosphoglycerate mutase 1.

Zhang Y, Cao Y, Wu X, Chen Z, Chen B, Wang A Nat Commun. 2024; 15(1):8936.

PMID: 39414782 PMC: 11484934. DOI: 10.1038/s41467-024-53238-w.

Ethanolic extract from Sophora moorcroftiana inhibit cell proliferation and alter the mechanical properties of human cervical cancer.

Guo M, Guo D, Liao L, Zhang X, Wang Z, Zhou Q BMC Complement Med Ther. 2024; 24(1):212.

PMID: 38831394 PMC: 11149180. DOI: 10.1186/s12906-024-04502-5.

Energy stress-induced circDDX21 promotes glycolysis and facilitates hepatocellular carcinogenesis.

Luo J, Yang Y, Zhang G, Fang D, Liu K, Mei Y Cell Death Dis. 2024; 15(5):354.

PMID: 38773094 PMC: 11109331. DOI: 10.1038/s41419-024-06743-1.

Phosphoglycerate mutase 1 promotes breast cancer progression through inducing immunosuppressive M2 macrophages.

Zhang D, Wang M, Ma S, Liu M, Yu W, Zhang X Cancer Gene Ther. 2024; 31(7):1018-1033.

PMID: 38750301 DOI: 10.1038/s41417-024-00769-5.

References

Jin X, Yang Y, Chen K, Lv Z, Zheng L, Liu Y . HDMCP uncouples yeast mitochondrial respiration and alleviates steatosis in L02 and hepG2 cells by decreasing ATP and H2O2 levels: a novel mechanism for NAFLD. J Hepatol. 2009; 50(5):1019-28. DOI: 10.1016/j.jhep.2008.10.034. View

Mashima T, Seimiya H, Tsuruo T . De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 2009; 100(9):1369-72. PMC: 2694429. DOI: 10.1038/sj.bjc.6605007. View

El-Serag H, Marrero J, Rudolph L, Reddy K . Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008; 134(6):1752-63. DOI: 10.1053/j.gastro.2008.02.090. View

Chen Y, Lin M, Yao H, Wang H, Zhang A, Yu J . Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology. 2007; 46(1):200-8. DOI: 10.1002/hep.21668. View

Gillies R, Gatenby R . Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?. J Bioenerg Biomembr. 2007; 39(3):251-7. DOI: 10.1007/s10863-007-9085-y. View

Inoki K, Zhu T, Guan K . TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003; 115(5):577-90. DOI: 10.1016/s0092-8674(03)00929-2. View

Pelicano H, Martin D, Xu R, Huang P . Glycolysis inhibition for anticancer treatment. Oncogene. 2006; 25(34):4633-46. DOI: 10.1038/sj.onc.1209597. View

Chi J, Chang H, Wang N, Chang D, Dunphy N, Brown P . Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci U S A. 2003; 100(11):6343-6. PMC: 164448. DOI: 10.1073/pnas.1037853100. View

Kondoh H, LLeonart M, Gil J, Wang J, Degan P, Peters G . Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005; 65(1):177-85. View

10.

Rigden D, Bagyan I, Lamani E, Setlow P, Jedrzejas M . A cofactor-dependent phosphoglycerate mutase homolog from Bacillus stearothermophilus is actually a broad specificity phosphatase. Protein Sci. 2001; 10(9):1835-46. PMC: 2253200. DOI: 10.1110/ps.15701. View

11.

Sakoda S, Shanske S, DiMauro S, Schon E . Isolation of a cDNA encoding the B isozyme of human phosphoglycerate mutase (PGAM) and characterization of the PGAM gene family. J Biol Chem. 1988; 263(32):16899-905. View

12.

Li Z, Huang C, Bai S, Pan X, Zhou R, Wei Y . Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach. Int J Cancer. 2008; 123(10):2377-83. DOI: 10.1002/ijc.23808. View

13.

Liu R, Li Z, Bai S, Zhang H, Tang M, Lei Y . Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. Mol Cell Proteomics. 2008; 8(1):70-85. DOI: 10.1074/mcp.M800195-MCP200. View

14.

Ariizumi S, Katagiri S, Katsuragawa H, Kotera Y, Yamamoto M . Sectionectomy is suitable for patients with T2 hepatocellular carcinoma according to the modified international union against cancer TNM Classification. Dig Surg. 2007; 24(5):342-8. DOI: 10.1159/000107714. View

15.

Gatenby R, Gillies R . Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004; 4(11):891-9. DOI: 10.1038/nrc1478. View

16.

Avila M, Berasain C, Sangro B, Prieto J . New therapies for hepatocellular carcinoma. Oncogene. 2006; 25(27):3866-84. DOI: 10.1038/sj.onc.1209550. View

17.

Chen G, Gharib T, Wang H, Huang C, Kuick R, Thomas D . Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A. 2003; 100(23):13537-42. PMC: 263849. DOI: 10.1073/pnas.2233850100. View

18.

Zhang J, Yu L, Fu Q, Gao J, Xie Y, Chen J . Mouse phosphoglycerate mutase M and B isozymes: cDNA cloning, enzyme activity assay and mapping. Gene. 2001; 264(2):273-9. DOI: 10.1016/s0378-1119(00)00597-7. View

19.

Tong A, Wu L, Lin Q, Lau Q, Zhao X, Li J . Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics. 2008; 8(10):2012-23. DOI: 10.1002/pmic.200700849. View

20.

de Atauri P, Repiso A, Oliva B, Vives-Corrons J, Climent F, Carreras J . Characterization of the first described mutation of human red blood cell phosphoglycerate mutase. Biochim Biophys Acta. 2005; 1740(3):403-10. DOI: 10.1016/j.bbadis.2004.11.023. View